X
Total 959151 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gonadotrophin-releasing hormone | ILX:0104718 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gorilla | ILX:0104719 | 5 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gorilla (birnlex 318) | ILX:0104720 | 5 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Goserelin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. Pharmacology: The pharmacokinetics of ZOLADEX have been determined in both male and female healthy volunteers and patients. In these studies, ZOLADEX was administered as a single 250g (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route. Mechanism of action: ZOLADEX is a synthetic decapeptide analogue of LHRH. ZOLADEX acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Drug type: Approved. Biotech. Drug category: Antineoplastic Agents. Antineoplastic Agents, Hormonal | ILX:0104721 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Government publication | ILX:0104722 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| GP94 parcel | Parcellation defined by Gasbarri A, Packard MG, Campana E, Pacitti C. Anterograde and retrograde tracing of projections from the ventral tegmental area to the hippocampal formation in the rat. Brain Res Bull. 1994;33(4):445-52. | ILX:0104723 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| GPBA receptor | ILX:0104724 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gq | ILX:0104725 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gracile fasciculus of medulla | Part of gracile fasiculus located in the medulla | ILX:0104727 | 11 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Gracile fasiculus of the spinal cord | Part of gracile fasciculus contained within the spinal cord | ILX:0104728 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Gracile nucleus | Nucleus in the caudal medulla that receive projections primarily from ipsilateral dorsal root ganglion cells via the posterior column of the spinal cord | ILX:0104729 | 10 | FDI Lab - SciCrunch.org | 11/30/2020 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Gracile nucleus of ABA 2009 | ILX:0104730 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gracilis nucleus intrinsic cell | ILX:0104731 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gracilis nucleus principal cell | ILX:0104732 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Gradient Echo Train Length | Number of gradient echoes collected per RF echo per shot (or excitation) per frame. A value of zero shall correspond to a pure RF echo frame. If RF Echo Train Length (0018,9240) is non zero and Gradient Echo Train Length is as well then only the central echo will be an RF Spin Echo, all others will be gradient echoes. | ILX:0104733 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Gradient Output | Unit is defined by Gradient Output Type (0018,9180). | ILX:0104734 | 5 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Gradient Output Type | Definition of gradient output unit, for which the value is stored in Gradient Output (0018,9182). Required if the system is capable of calculating Gradient Output (0018,9182). | ILX:0104735 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Gramicidin D | 15 residue peptide isolated from Bacillus brevis. With alternating D and L amino acids Pharmacology: Gramicidin is particularly effective against gram-positive bacteria. Because the drug is highly hemolytic, it cannot be administered internally and so is used only on the skin as a lotion or ointment. It is used primarily in the treatment of infected surface wounds, and in eye, nose, and throat infections. It is normally given with two other antibiotics (neomycin and polymixin B) as an ophthalmic solution Mechanism of action: Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization. This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death. Drug type: Approved. Biotech. Drug category: Anti-Infectives. Antibiotic Agents. Antibiotics. Ophthalmic Antibiotic. Topical Antibiotic | ILX:0104736 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Granisetron | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients. (PubChem) Pharmacology: Not Available Mechanism of action: Granisetron is a potent, selective antagonist of 5-hydroxytryptamine (serotonin) subtype 3 (5-HT 3) receptors. 5-HT 3 receptors are present peripherally on vagal nerve terminals and centrally in the area postrema of the brain. Cytotoxic drugs and radiation damage gastrointestinal mucosa, causing the release of serotonin from the enterochromaffin cells of the gastrointestinal tract. Stimulation of 5-HT 3 receptors causes transmission of sensory signals to the vomiting center via vagal afferent fibers to induce vomiting. By binding to 5-HT 3 receptors, granisetron blocks vomiting mediated by serotonin release. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). Drug type: Approved. Investigational. Small Molecule. Drug category: Antiemetics. Serotonin Antagonists | ILX:0104737 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Grant number | ILX:0104738 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X